DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV, and Codexis, Inc. announced the signing of an enzyme supply agreement.
The agreement grants DSM rights to use Codexis’ custom biocatalysts and services, and secures supply of Codexis enzymes for commercialization of sustainable enzyme-based pharmaceutical manufacturing routes developed by DSM’s InnoSyn route scouting services.
Codexis technology enables development of new efficient manufacturing processes for active pharmaceutical ingredients and intermediates which reduce cost and environmental waste. Codexis technology is used at major pharmaceutical and chemical companies worldwide including Merck, Pfizer and Teva.
The DSM InnoSyn route scouting team provides value creating solutions to its customer by integrating cutting edge enzyme technology with the full range of advances in synthetic methods such as homogeneous catalysis, modern organic synthesis and continuous chemistry, using for example micro reactors. The new routes result in increased efficiency of the manufacturing processes while reducing cost and environmental impact.
“Codexis has a proven track record over nearly 10 years in bringing innovation and manufacturing efficiency to our partners,” said Joseph Sarret, president, Codexis Pharmaceutical Services & Enzyme Products. “We are pleased to collaborate with DSM in the field of biocatalysis to enable cost-effective manufacturing process at commercial scale.”
Oliver May, Corporate Scientist and Business Manager for DSM’s InnoSyn route scouting services commented: “One important success factor for implementing enzymatic routes is access to a diverse range of biocatalysts. DSM is continuously expanding its unique enzyme collection of more than 3000 enzymes by in-house developments as well as innovative partnering models. We are very pleased to collaborate with Codexis whose expertise in enzyme development perfectly matches with DSM’s capabilities to identify, develop and implement efficient enzymatic routes.”
InnoSyn is a trademark of DSM
Codexis is a clean technology company that develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis’ technology is commercialized with many leading global pharmaceutical companies and in development for advanced biofuels with Shell. Other potential markets include carbon capture, water treatment and chemicals.
DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries.
DSM – the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates solutions that nourish, protect and improve performance.